IL6 and chronic kidney disease: Taken together, these studies [12,13] reinforce the robustness of IL-6 as a biomarker across CKD populations, while our work specifically extends this evidence to the hemodialysis setting, where cardiac remodeling is accelerated and clinically relevant.